# Moderna says individualized mRNA melanoma therapy met Phase 3 endpoints

_Wednesday, August 19, 2026 at 8:16 AM EDT · Science, Products · Latest · Tier 2 — Notable_

Moderna and Merck announced positive Phase 3 results for intismeran autogene, an individualized mRNA therapy used with Keytruda after complete resection of stage IIB-IV melanoma. Moderna said the study met its primary recurrence-free-survival endpoint and a key secondary endpoint for distant metastasis-free survival. The company described the result as the first positive Phase 3 outcome for an individualized neoantigen therapy and for an mRNA-based cancer therapy.

## Sources

- [twitter.com](https://twitter.com/NoubarAfeyan/status/2090050162441752787)

---
Canonical: https://techandbusiness.org/newswire/nQJlH-BCUlFecghRmCpg07
Retrieved: 2026-08-19T16:29:28.496Z
Publisher: Tech & Business (techandbusiness.org)